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Abstract
Background—Sequence variants located at 15q25 have been associated with lung cancer and
propensity to smoke. We recently reported an association between rs16969968 and risk of upper
aerodigestive tract (UADT) cancers (oral cavity, oropharynx, hypopharynx, larynx and esophagus)
in women (odds ratio (OR) =1.24, P=0.003) with little effect in men (OR=1.04, P=0.35).
Methods—In a coordinated genotyping study within the International Head and Neck Cancer
Epidemiology (INHANCE) consortium, we have sought to replicate these findings in an additional
4,604 cases and 6,239 controls from 10 independent UADT cancer case-control studies.
Results—rs16969968 was again associated with UADT cancers in women (OR=1.21, 95%
confidence interval(CI)=1.08–1.36, P=0.001) and a similar lack of observed effect in men
(OR=1.02, 95%CI=0.95–1.09, P=0.66) (P-heterogeneity=0.01). In a pooled analysis of the
original and current studies, totaling 8,572 UADT cancer cases and 11,558 controls, the
association was observed among females (OR=1.22, 95%CI=1.12–1.34, P=7×10−6) but not males
(OR=1.02, 95%CI=0.97–1.08, P=0.35) (P-heterogeneity=6×10−4). There was little evidence for a
sex difference in the association between this variant and cigarettes smoked per day, with male
and female rs16969968 variant carriers smoking approximately the same amount more in the
11,991 ever smokers in the pooled analysis of the 14 studies (P-heterogeneity=0.86).
Conclusions—This study has confirmed a sex difference in the association between the 15q25
variant rs16969968 and UADT cancers.
Impact—Further research is warranted to elucidate the mechanisms underlying these
observations.
Keywords
genetic variants; 15q25; nicotinic acetylcholine receptor; upper aerodigestive tract cancers;
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Exposure to alcohol and tobacco are the major risk factors for upper aerodigestive tract
(UADT) cancers (cancers of the oral cavity, oropharynx, hypopharynx, larynx, and
esophagus) in Europe and America (1).
Common genetic variants located at chromosome 15q25, a locus that contains three genes
that encode nicotinic acetylcholine receptor (nAChR) subunits (CHRNA5, CHRNA3 and
CHRNB4), have been implicated in the risk of lung cancer, chronic obstructive pulmonary
disease (COPD) and peripheral arterial disease (2–5). The same variants are associated with
increased propensity to smoke tobacco (4,6–7), leading to the hypothesis that this might
explain the associations noted with pathologies linked to tobacco exposure (4,8). Others
have suggested that these variants may have additional independent effects (2,5,9–11). In a
recent study of 3,968 UADT cancer cases and 5,319 controls (10), we observed that there
was statistically significant association between 15q25 variant rs16969968 and risk of
UADT cancers in women (OR=1.24, 95% CI=1.08–1.42, P=0.003) but not men (OR=1.04,
95%CI=0.96–1.12, P=0.35) (P-heterogeneity=0.03). In the present study, we sought to
validate these findings in an independent series of 4,604 UADT cancer cases and 6,239
controls from 10 UADT cancer case-control studies participating in the International Head
and Neck Cancer Epidemiology (INHANCE) consortium (12).
Materials and Methods
Study subjects
Ten independent case-control studies of UADT cancers from INHANCE consortium (seven
were conducted in America and three in Europe) participated in our present study. Study
designs and population characteristics have been described in more detail previously (12–
15), and are briefly described in Table 1 and Supplementary Table 1. All the subjects
included in the pooled analysis were of self-reported European ancestry. As previously
described (12), all INHANCE studies have extensive information on tumor site and
histology, as well as lifestyle characteristics. The majority of hospital-based studies
excluded controls with tobacco-related pathologies as a control source (13–15). The
exceptions were the Penn State, Rome, MD Anderson and Pittsburgh studies that did not
exclude tobacco-related pathologies specifically. Written informed consent was obtained
from all study subjects, and studies were approved by the institutional review boards at each
study center. Analysis was restricted to squamous cell carcinomas.
Genotyping and quality control
Genotyping of the 15q25 variant, rs16969968, was carried out in eight genotyping
laboratories (Supplementary Table 1) using the TaqMan genotyping platform (rs16969968
Taqman assay primers GAGTGGTAGTGGACCAAAATCTTCT and
ACCTCACGGACATCATTTTCCTT probes VIC-MGB-CTGCGCTCAATTC, FAM-
MGB-CTGCGCTCGATTC). A common series of 90 standard DNAs were genotyped at
each laboratory to ensure the quality and comparability of the genotyping results across the
different studies. The overall concordance with the consensus genotype and the genotypes
from the eight laboratories for the standardized DNAs was 99.86%. Genotype success rate
was greater than 95.87% across each site and genotype distributions were consistent with
that expected by Hardy–Weinberg equilibrium (HWE).
Statistical analysis
The association between rs16969968 and UADT cancer risk was estimated by odds ratio
(ORs) and 95% confidence intervals (CIs) per allele (under log-additive model) and
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genotype derived from multivariate unconditional logistic regression, with age, sex and
study site (or country when appropriate) included in the model as covariates. Heterogeneity
of ORs was assessed using the Cochran’s Q test. The association between the rs16969968
variant allele and number of cigarettes smoked per day (CPD) was carried out in ever
smokers using multivariate linear regression on log transformed data. Mean values and 95%
CIs were calculated in the combined initial and present data sets with adjustment for age,
sex and study site (and case/control status when appropriate). Differential effect of this SNP
on CPD between sexes was evaluated in a linear regression analysis by including a genotype
by sex interaction term.
Results
In the independent series of 4,604 UADT cancer cases and 6,239 controls, the association
between rs16969968 and UADT cancers was found in women (OR=1.21, 95%CI=1.08–
1.36, P=0.001), with little evidence for association in men (OR=1.02, 95%CI=0.95–1.09,
P=0.66) (P-heterogeneity=0.01) (Figure 1). This is consistent with the observation in the
initial study (OR=1.24, 95%CI=1.08–1.42 for women; OR=1.04, 95%CI=0.96–1.12 for
men; P-heterogeneity=0.03) (10), To further evaluate this genetic effect, we pooled
individual level data from the initial study and the 10 independent studies presented here,
making for a total of 8,572 UADT cancer cases and 11,558 controls from 14 studies. We
then conducted stratified analysis in both women and men (Figure 1). In the combined
series, rs16969968 was associated with UADT cancers only in females (Females: OR=1.22,
95%CI=1.12–1.34, P=7×10−6; Males: OR=1.02, 95%CI=0.97–1.08, P=0.35; P-
heterogeneity=6×10−4). In women the association of rs16969968 with UADT cancer risk
was relatively consistent among subgroups stratified by smoking status, alcohol
consumption and age. Significant heterogeneity was noted by UADT cancer subsite (P-
heterogeneity=0.02), with the association strongest among female laryngeal cancer
(OR=1.40, 95%CI=1.21–1.61, P=6×10−6) and absent in female cancers of the oropharynx
(OR=1.00, 95%CI=0.84–1.18, P=0.97) and hypopharynx (OR=0.95, 95%CI=0.63–1.43,
P=0.80). Evidence for association was also present in female never smokers (OR=1.18,
95%CI=1.00–1.39, P=0.05) and never drinkers (OR=1.35, 95%CI=1.14–1.61, P=6×10−4).
In contrast, in men there was little evidence for association between rs16969968 and UADT
cancers in any stratum.
The rs16969968 variant has been consistently associated with propensity to smoke cigarettes
(particularly CPD) (4,6–7), we therefore examined whether rs16969968 was associated with
CPD among 11,991 ever smokers included in the combined initial and present data sets, as
well as in UADT cancer cases and controls separately and among males and females (Table
2). In the combined series the rs16969968 minor allele was associated with CPD
(P=1×10−6), with rare homozygotes ever smoking carriers smoking 1.72 CPD more than
common homozygotes. There was little evidence for a sex difference in the effect of the
rs16969968 variant on CPD, with male and female smoking variant carriers smoking
approximately the same amount more (male and female rare homozygotes smoked 1.79 and
1.29 CPD more than common homozygotes, respectively) (P-heterogeneity=0.86) (Table 2).
Similar patterns were observed in cases and controls when analyzed separately (P-
heterogeneity=0.51 and 0.99, respectively).
Discussion
This study has replicated our previous observation of a sex difference in the association
between the 15q25 variant rs16969968 and UADT cancers. In a combined analysis, the
association was highly significant in women (P=7×10−6) but not men (P=0.35) with strong
evidence for heterogeneity (P-heterogeneity=10−4) arguing against a chance finding. Under
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the hypothesis that the association between the rs16969968 variant and tobacco related
pathologies is mediated by this variant's effect on propensity to smoke, an association in
UADT cancers, and particularly in laryngeal cancers, would be expected. However, the
observation of a sex difference in the association with UADT cancers is intriguing for
several reasons. Firstly, extrapolating from the observed effect of rs16969968 on CPD, only
a small OR of approximately 1.02 for UADT cancers is expected in both men and women
(Supplementary method and Supplementary Table 2). This corresponds closely with
observation of association between UADT cancers and rs16969968 in men but risk observed
in women is much higher. Secondly, as reported here (Table 2) and elsewhere (4,6), there is
little evidence for a sex difference in the association between rs16969968 and CPD. This
association could be potentially caused by a sex difference in the association between the
15q25 variant and smoking propensity not captured by the crude smoking measures
available to this study. Nevertheless, if this association was caused by such a sex difference
in propensity to smoke, one might expect the sex difference in this association to manifest
more strongly in a cancer such as lung cancer, where the risks associated with tobacco
consumption are more pronounced. However, to date, there is only inconsistent evidence for
a sex difference in the association between this 15q25 variant and lung cancer (9–11). This
seems to imply that rs16969968 has additional effects on UADT cancer susceptibility than
just increasing propensity to smoke, as has been suggested for lung cancer (2, 9–11).
nAChRs are expressed throughout the UADT, and have been shown to mediate
pathobiologic effects of tobacco and nicotine derivatives in the stratified epithelium lining
the upper digestive tract (16–19). The rs16969968 SNP causes a change in amino acid 398
from asparagine (encoded by the G allele) to aspartic acid (encoded by A allele) in the
second intracellular loop of the a5 subunit, and there is some evidence to suggest that this
change alters nAChR function in response to nicotine agonist in vitro (20). However, the
functional consequences of this alteration in UADT carcinogenesis remain to be established.
In our study, the strongest association with 15q25 variant was observed among female
laryngeal cancer. The male-to-female ratio in laryngeal cancer is 4.7 :1 in America (21) and
11.3 :1 in Europe (22), one of the highest among all cancer sites. It is worth noting that the
difference in susceptibility to larynx cancer based on gender has remained unchanged
through the years despite the increasing tobacco and alcohol consumption among women.
The larynx is influenced by sexual hormones during the fetal development, as well as
puberty and adulthood as it is subject to laryngeal epithelial layer modifications, cartilage
metaplasia, and morphostructural changes (23–24). These considerations, in association with
the epidemiological evidence, has led to the speculation that sex hormones might be
involved in the carcinogenesis process (25). Our finding of sex-specific effect of 15q25
variant may add to the knowledge in understanding the underlying mechanism of sex
difference in susceptibility to laryngeal cancer. Although speculative, there has been some
data linking nAChR signaling to sex hormones. For example, some studies have shown that
steroid hormones, including progesterone, are noncompetitive antagonists of nAChR (26–
27). Additionally, a putative progesterone responsive element was found to be present in the
promoter of α5 nAChR subunit, and progesterone has been shown to have an effect on α5
expression level both in vitro and in vivo (28). It is biologically plausible that the interplay
between sex hormones and α5-containing nAChR may play a direct or indirect role in
mediation of sex difference in susceptibility to laryngeal cancer. Nevertheless, such
speculation needs to be further tested in in-depth molecular mechanistic studies in the future.
Several limitations are present in this pooled study. First, the observed sex-specific
association could potentially be caused by a difference in variant frequency in controls
between sexes (caused by, for example, population stratification or a sex-specific
ascertainment bias due to pathology type in hospital-based studies). However, there was
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little difference in the frequency of rs16969968 variant between male and female controls in
any of the studies (Supplementary Table 3). Second, the information on human
papillomavirus (HPV) infection, involved in the etiology of UADT cancers, particularly
orophayrngeal cancers (29), was not available in our study. Interestingly, there was little
evidence for an association between 15q25 variant and oropharyngeal cancer. Further
studies including HPV infection status may help to clarify whether the effect of 15q25
variant are different in HPV-positive and HPV-negative oropharyngeal cancers.
In summary, this study has replicated the association between 15q25 variant rs16969968 and
risk of UADT cancers in women, particularly prominent for laryngeal cancer. By contrast,
there is little effect in men, implying a sex-specific effect. The biological basis for this
association remains unclear and additional study appears warranted to further validate and
explore these findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Forest plots representing the association between rs16969968 and UADT cancer risk in
women, men and the combined series, respectively. Unless specified, the ORs, and 95% CIs
were derived from the log-additive genetic model with adjustment for age, study site and sex
when appropriate. P for heterogeneity was derived from the Cochran’s Q test. The overall
OR is shown by the dotted vertical line. For each study among drinkers, individuals were
defined as light drinkers if they consumed below the median level of ethanol per day;
otherwise they were considered as heavy drinkers.
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